Zymeworks(ZYME)
MIDDLETOWN, DEBiotechnology
Focus: Zymeworks is a public biotechnology company specializing in in silico biologics development, with a focused pipeline in oncology and immunology. The company operates at mid-cap scale (~750 employees) with a clinical-stage portfolio of 7 programs across early-to-mid phase development.
Profile data last refreshed 4h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Employees
501-1000
Open Jobs
5+1 this month
Stable — net +1 jobs in 30d
3 added, 2 removed. Backfill posture.
Should You Work at Zymeworks?
AI assessmentZymeworks is a high-risk, high-science opportunity for R&D professionals willing to tolerate financial volatility and early-stage clinical timelines in exchange for deep technical exposure to computational drug design.
Why Work Here
- R&D-driven culture with 189% R&D intensity and 3 of 4 open roles in Research & Development, indicating deep investment in drug discovery infrastructure.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$76M
Pipeline & Clinical Trials
PHASE_1
Clinical Trials (1)
NCT06555744A Study of ZW191 in Participants With Solid Tumors
Phase 1Help build intelligence for Zymeworks
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.